Join to View Full Profile
1500 East Medical Center Dr1ST floor Taubman CTR Recp CAnn Arbor, MI 48109
Phone+1 734-936-9010
Dr. Mikol is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Neurology, 1993 - 1996
University of ChicagoInternship, Internal Medicine, 1992 - 1993
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1992
Clinical Trials
- Atacicept in Multiple Sclerosis Extension Study, Phase II Start of enrollment: 2009 Mar 01
Publications & Presentations
PubMed
- 2 citationsEfficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, David Dolezil, Raquel Gil-Gouveia
JAMA Neurology. 2024-09-16 - 3 citationsLong-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.Stewart J Tepper, Richard B Lipton, Stephen D Silberstein, David Kudrow, Messoud Ashina
Headache. 2023-06-01 - 3 citationsLong-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.Messoud Ashina, Stewart J Tepper, Jan Lewis Brandes, Uwe Reuter, Guy P Boudreau
Headache. 2022-05-01
Journal Articles
- Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – the Migraine Functional Impact Questionnaire (MFIQ)Daniel D Mikol, Dawn C Buse, Wiley
- A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients with Stable AnginaAmaal Starling, Daniel D Mikol, Headache: The Journal of Head and Face Pain
Press Mentions
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291February 14th, 2023- NervGen Completes Dosing Another Group with MS Candidate NVG-291November 18th, 2022
- NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)May 16th, 2022
- Join now to see all
Grant Support
- Effect Of Body Cooling By RTX On Motor Function In Heat-Sensitive MS PatientsNational Center For Research Resources2007
- Caveolin-1/Lgf-Ir Interactions In OligodendrocytesNational Institute Of Neurological Disorders And Stroke2002–2004
- Oligodendrocyte/Myelin Glycoprotein And The PNational Institute Of Neurological Disorders And Stroke1997–2001
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
